Verastem, Inc.
VSTM evidence brief
What we can confirm
- BioSniper Score:
- 5.2 / 10
- Market Cap:
- $690.1M
- Lead Asset:
- avmapki fakzynja co-pack (Approved)
What it means
What to watch
Prepared research question
What matters most for VSTM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VSTM
Verastem, Inc. is a biopharmaceutical company developing small-molecule inhibitors targeting RAS pathway-driven cancers, with a commercial product for KRAS-mutated low-grade serous ovarian cancer and a pipeline including avutometinib, defactinib, and VS-7375.
Key risk: Clinical-stage pipeline
BioSniper Score
Based on 5 of 6 signals
Market Cap
$690.1M
Cash Runway
—
Lead Asset
avmapki fakzynja co-pack (Approved)Next Catalyst
Patent_Expiry · Dec 29, 2042Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 15 clinical trials · 1 catalyst · 1 FDA decision for Verastem, Inc..
Verastem, Inc. is a biopharmaceutical company developing small-molecule inhibitors targeting RAS pathway-driven cancers, with a commercial product for KRAS-mutated low-grade serous ovarian cancer and a pipeline including avutometinib, defactinib, and VS-7375.
- Cash & equivalents of $136.4M as of 2026-06-30 [sec].
- Total revenue of $40.1M and net income of -$34.7M as of 2026-06-30 [sec].
- Shareholders' equity of $50.0M as of 2026-06-30 [sec].
- RAMP 205 trial (avutometinib + defactinib + chemo) in front-line metastatic PDAC showed a confirmed ORR of 83% (10/12) at dose level 1 [sec · filed 2026-04-09].
- VS-7375, a KRAS G12D inhibitor, entered Phase 1/2 in mid-2025; GenFleet's GFH375 (same compound) received Breakthrough Therapy Designation in China in April 2026 [sec · filed 2026-04-09][sec_mda · as of 2026-05-07].
What works
- RAMP 205 trial in front-line metastatic PDAC achieved a confirmed ORR of 83% (10/12) at the selected RP2D, supported by an FDA orphan drug designation [sec · filed 2026-04-09].
- VS-7375 is a dual ON/OFF KRAS G12D inhibitor with a differentiated profile versus ON-only inhibitors, and the partner GenFleet obtained Breakthrough Therapy Designation in China [sec · filed 2026-04-09][sec_mda · as of 2026-05-07].
- The company has a commercial product (AVMAPKI FAKZYNJA CO-PACK) for KRAS-mutated low-grade serous ovarian cancer, indicating a transition to a fully integrated biopharmaceutical company [news · published 2026-09-22][sec · filed 2026-04-09].
What to weigh
- Net income was -$34.7M as of 2026-06-30, indicating ongoing operating losses [sec].
- VS-7375 is still in early clinical development (Phase 1/2), with no approved product yet, and faces competition from other RAS inhibitors [sec · filed 2026-04-09].
- The company relies on a single commercial product and a pipeline of unapproved assets, creating concentration risk [news · published 2026-09-22].
From the filings
Quoted directly from source documents.
RAMP 205 trial ORR
“confirmed overall response rate ("ORR") of 83% (10/12) patients”
SEC filings · April 9, 2026
VS-7375 dual ON/OFF inhibition
“dual potent inhibition of both ON and OFF states of KRAS G12D correlates with better in vivo efficacy and durability versus ON-only RAS inhibitors”
SEC filings · April 9, 2026
GenFleet Breakthrough Therapy Designation
“GFH375 was granted Breakthrough Therapy Designation”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2042-12-29 · Patent_Expiry · AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE — Patent expiry for NDA219616; no near-term impact on exclusivity.
Risks & what to watch (4)›
Key risks
- Clinical-stage pipeline — Most assets (VS-7375, avutometinib/defactinib combos) are not yet approved; regulatory and commercial success uncertain [sec · filed 2026-04-09].
- Operating losses — Net income of -$34.7M as of 2026-06-30; cash burn may require future financing [sec].
- Competition in KRAS G12D — Multiple companies are developing KRAS G12D inhibitors; VS-7375 may face market share challenges [sec · filed 2026-04-09].
- Patent expiry risk — Patent expiry for avutometinib potassium and defactinib hydrochloride on 2042-12-29, but far off [catalyst].
What to watch
- Update on TARGET-D 101 trial expected in second half of 2026 [sec · filed 2026-06-23].
- VS-7375 clinical data update expected in October 2026 [sec_mda · as of 2026-08-06].
- Completion of enrollment across all three TARGET-D phase 2 trials by end of 2026 [sec_mda · as of 2026-08-06].
- FDA meeting before end of 2026 to review Phase 3 pivotal trial designs in 1L metastatic PDAC [sec_mda · as of 2026-08-06].
Sources: News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Verastem, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Verastem, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.13 · 0% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~5920d
0 buys · 5 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 20.1%
- Days to cover
- 8.4
- Shares short
- 17,523,588
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VSTM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Verastem, Inc.?
Verastem, Inc. is a biopharmaceutical company developing small-molecule inhibitors targeting RAS pathway-driven cancers, with a commercial product for KRAS-mutated low-grade serous ovarian cancer and a pipeline including avutometinib, defactinib, and VS-7375.
What is Verastem, Inc.'s lead drug candidate?
Verastem, Inc.'s most advanced tracked candidate is avmapki fakzynja co-pack (Approved) for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
What is Verastem, Inc.'s next catalyst?
Verastem, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA219616" — expected December 29, 2042.
Who is the CEO of Verastem, Inc.?
Mr. Daniel W. Paterson is the chief executive officer of Verastem, Inc. (VSTM).
Where is Verastem, Inc. headquartered?
Verastem, Inc. (VSTM) is headquartered in Needham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.